| 申請系所(單位) |
生醫工程研究所 |
| 計畫主持人 |
王惠民 教授 ( 個人網頁 ) |
| 計畫名稱(中文) |
雙反應水膠液珠與介電泳分離技術發展個人化精準醫療之抗癌藥物快速評估平台 |
| 計畫名稱(英文) |
A fast estimation platform of anticancer drugs for personal precision medicine by using double reaction hydrogel droplet and dielectrophoretic separation technique |
| 共同主持人 |
吳靖宙 教授 / 生物產業機電工程學系 |
| 協同主持人 |
|
| 中文摘要 |
本計畫利用液珠微流體系統，對皮膚癌細胞進行三維培養，結合泳道設計與介電泳 (dielectrophrosis, DEP) 控制建立無須抗體標定與螢光散射判讀系統之細胞分選平台，並應用於抗癌物質在皮膚癌細胞 (B16F10) 之藥物快速篩選，有助於個人化精準醫療的推動。在臨床醫生啟動完整療程前，藉由水膠三維培養仿生細胞的藥物反應與液珠微流體系統低樣本量的優勢，從罹癌病人取得少量的癌細胞即能進行藥物篩選，快速得知最有利於個體病人治療的抗癌藥物，將可大大減少現行藥物治療的不確定性與時間/金錢的花費，並增加病人治癒的機率。 |
| 英文摘要 |
This project used a liquid bead microfluidic system to conduct three-dimensional culture of skin cancer cells, combined with lane design and dielectrophrosis (DEP) control to establish a cell sorting platform that does not require antibody calibration and fluorescence scattering interpretation systems, and is applied to the rapid screening of cancer substances in skin cancer cells (B16F10) is helpful to the promotion of personalized precision medicine. Before clinicians start a complete course of treatment, by taking advantage of the drug response of hydrogel three-dimensional cultured bionic cells and the advantage of the low sample volume of the liquid bead microfluidic system, a small amount of cancer cells can be obtained from cancer patients for drug screening. Anti-cancer drugs that are beneficial to the treatment of individual patients will greatly reduce the uncertainty and time/money cost of current drug treatment, and increase the patient′s chance of cure. |
